Ephraim A. Ansa-Addo

Ephraim A. Ansa-Addo

Auto-generated profile, based on publicly available information

Ephraim A. Ansa-Addo

Division of Medical Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Journal of Hepatology
Verified
Journal Article
Closed access
HWHan Wang
Han Wang
HZHongji Zhang
Hongji Zhang
YWYu Wang
Yu Wang
ZBZachary J. Brown
Zachary J. Brown
YXYujia Xia
Yujia Xia
ATAllan Tsung
Allan Tsung

29 May 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
EAEphraim A. Ansa-Addo
Ephraim A. Ansa-Addo
HHHuai-Cheng Huang
Huai-Cheng Huang
BRBrian Riesenberg
Brian Riesenberg
SISupinya Iamsawat
Supinya Iamsawat
DBDavis Borucki
Davis Borucki
ZLZihai Li
Zihai Li
Distinct lineages of T cells can act in response to various environmental cues to either drive or restrict immune-mediated pathology. Here, we identify the RNA binding protein, poly(C)-binding protein 1 (PCBP1) as an intracellular immune checkpoint that is up-regulated in activated T cells to prevent conversion of effector T (Teff) cells into regulatory T (Treg) cells, by restricting the expression of Teff cell–intrinsic Treg commitment programs. This was critical for stabilizing Teff cell functions and subverting immune-suppressive signals. T cell–specific deletion of Pcbp1 favored Treg cell differentiation, enlisted multiple inhibitory immune checkpoint molecules including PD-1, TIGIT, and VISTA on tumor-infiltrating lymphocytes, and blunted antitumor immunity. Our results demonstrate a critical role for PCBP1 as an intracellular immune checkpoint for maintaining Teff cell functions in cancer immunity.

17 September 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
PAParviz Azimnasab-Sorkhabi
Parviz Azimnasab-Sorkhabi
MSMaryam Soltani-Asl
Maryam Soltani-Asl
JJJose Roberto Kfoury Junior
Jose Roberto Kfoury Junior
EAEphraim A. Ansa-Addo
Ephraim A. Ansa-Addo
Distinct from conventional Foxp3+ regulatory T cells (Tregs), T-bet+ Tregs represent a stable subset of immunosuppressive T cells characterized by co-expression of the transcription factors (TFs) Foxp3 and T-bet. Given that Tregs were also reported to co-express Foxp3 together with effector T cell TFs such as GATA3, or RORγt, we propose the term hybrid Tregs (hTregs) to distinguish between these Tregs that co-express Foxp3 together with effector T cell TFs from conventional Foxp3+ Tregs. Therefore, this review will focus on hTreg cells, a specific subset of CD4+ T cells, and discuss the different types of hTregs with particular emphasis on T-bet+ hTregs. T-bet+ hTregs exhibit unique features including IFN-γ production, high expression of immune checkpoints (PD-1, CTLA-4, GITR, OX40, TIGIT), and chemokine receptors (CXCR3, CCR5). Through secretion of IL-10, TGF-β and IFN-γ, T-bet+ hTregs modulate both innate and adaptive immune responses within the tumor microenvironment (TME). Their high expression of CD73 contributes to adenosine-mediated immunosuppression, while CXCR3 and CCR5 facilitate their recruitment to inflammatory sites. T-bet+ hTregs were reported to accumulate in multiple human cancers, including lung, ovarian, and colorectal carcinomas. Despite these advancements, the function of hTregs in diseases such as cancer remains poorly understood, and requires further investigations. For instance, some studies suggest T-bet+ hTregs to be anti-inflammatory due to their production of IL-10, TGF-β, and superior suppressive capacity compared to conventional Tregs. Yet, other studies have reported that T-bet+ hTregs exhibit enhanced proinflammatory functions in colitis and other pathologies. We will then highlight current known mechanisms that promote the differentiation and functions of T-bet+ hTregs in cancer. Lastly, we will discuss the advancements and opportunities for therapeutic targeting of T-bet+ hTregs in cancer immunotherapy.

7 October 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
EAEphraim A. Ansa-Addo
Ephraim A. Ansa-Addo
PAParviz Azimnasab-Sorkhabi
Parviz Azimnasab-Sorkhabi
HHHuai-Cheng Huang
Huai-Cheng Huang
BRBrian P. Riesenberg
Brian P. Riesenberg
MBMusab Bouhajra
Musab Bouhajra
ZLZihai Li
Zihai Li
Regulatory T cells (Tregs) are essential for maintaining immune homeostasis and preventing autoimmune diseases, but are also a major cellular constituent of the tumor microenvironment (TME) that facilitates cancer progression. Identifying differences in Treg subtypes to specifically disrupt the activities of tumor-promoting Tregs, without affecting Tregs that maintain immune homeostasis remain a challenge. Here, we report that expression of the chromatin-organizer protein special AT-rich sequence binding protein 1 (Satb1), in Tregs is critical for their tumor-promoting functions in the TME, but not strictly required to suppress inflammatory T cells in autoimmune colitis. Satb1 expression differentiated between two Treg subtypes with distinct display of Treg phenotypic markers in lymphoid organs. Using transfer experiments, we discovered a context-specific switch in Satb1 protein expression between the two Treg subtypes. In mice, Treg-specific deletion of Satb1 augmented TCF-1 expression via a signaling axis involving Stat3 and the RNA-binding protein poly(C)-binding protein 1 (PCBP1), impairing the activities of tumor-infiltrating Treg cells. Simultaneous deletion of Satb1 and PCBP1 in Tregs completely restored Treg pro-tumorigenic functions and abolished the potent antitumor immune responses observed in Satb1-deficient mice. Our results reveal a key mechanism that may safely and potently enhance antitumor immunity without causing systemic autoimmune diseases.

29 August 2024
Verified
Book Chapter
Closed access
PDF file
PAParviz Azimnasab-sorkhabi
Parviz Azimnasab-sorkhabi
MSMaryam Soltani-Asl
Maryam Soltani-Asl
EAEphraim A. Ansa-Addo
Ephraim A. Ansa-Addo
JJJose Roberto Kfoury Junior
Jose Roberto Kfoury Junior